RUSSO, FRANCESCO PAOLO
 Distribuzione geografica
Continente #
NA - Nord America 725
EU - Europa 688
AS - Asia 121
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.535
Nazione #
US - Stati Uniti d'America 723
PL - Polonia 351
RU - Federazione Russa 157
IT - Italia 52
SE - Svezia 52
IE - Irlanda 42
SG - Singapore 33
CN - Cina 32
HK - Hong Kong 25
VN - Vietnam 20
GB - Regno Unito 6
BE - Belgio 5
BG - Bulgaria 5
FI - Finlandia 5
IN - India 5
DE - Germania 4
JO - Giordania 4
CZ - Repubblica Ceca 3
CA - Canada 2
ES - Italia 2
KR - Corea 2
NL - Olanda 2
UA - Ucraina 2
EU - Europa 1
Totale 1.535
Città #
Warsaw 350
Santa Clara 278
Fairfield 75
Dublin 42
Ashburn 35
Woodbridge 35
Chandler 33
Cambridge 31
Singapore 30
Houston 29
Seattle 25
Florence 22
Beijing 19
Wilmington 19
Altamura 18
Ann Arbor 18
Dong Ket 18
Lawrence 18
Hong Kong 16
Princeton 11
Buffalo 10
Dearborn 8
Boston 7
Brussels 5
Mumbai 5
Norwalk 5
Sofia 5
Helsinki 4
Medford 4
San Diego 4
Brno 3
Castelliri 3
Grafing 3
Phoenix 3
Barcelona 2
Dronten 2
Kent 2
London 2
Moscow 2
Redmond 2
Shanghai 2
Toronto 2
Boardman 1
Chicago 1
Chiswick 1
Dalmine 1
Falkenstein 1
Falls Church 1
Hillsboro 1
Laurel 1
Quanzhou 1
Rome 1
Seoul 1
Shenzhen 1
Trumbull 1
Xuzhou 1
Yubileyny 1
Totale 1.222
Nome #
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 229
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 219
HepaDisk – A new quality of life questionnaire for HCV patients 160
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 157
AISF position paper on HCV in immunocompromised patients 151
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 146
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 132
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 126
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 116
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 116
Totale 1.552
Categoria #
all - tutte 3.762
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.762


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020169 0 0 0 0 0 30 35 32 25 20 23 4
2020/2021316 11 17 9 60 26 31 26 24 31 52 8 21
2021/202294 11 0 4 7 4 9 9 6 4 5 11 24
2022/2023202 22 43 23 2 8 38 27 16 18 1 3 1
2023/202449 0 8 11 1 4 2 1 16 1 0 3 2
2024/2025516 26 57 30 88 187 128 0 0 0 0 0 0
Totale 1.552